Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa
Background: KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as pe...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2023-06-01
|
| Series: | African Journal of Laboratory Medicine |
| Subjects: | |
| Online Access: | https://ajlmonline.org/index.php/ajlm/article/view/2065 |
| _version_ | 1827909629234905088 |
|---|---|
| author | Kerri-Lee A. Francois Nokukhanya Msomi Kerusha Govender Lilishia Gounder Pravi Moodley Raveen Parboosing Indrani Chetty Lunga Xaba Aabida Khan |
| author_facet | Kerri-Lee A. Francois Nokukhanya Msomi Kerusha Govender Lilishia Gounder Pravi Moodley Raveen Parboosing Indrani Chetty Lunga Xaba Aabida Khan |
| author_sort | Kerri-Lee A. Francois |
| collection | DOAJ |
| description | Background: KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as people living with HIV in KwaZulu-Natal, is unknown.
Objective: The study aimed to determine the prevalence of SARS-CoV-2 immunoglobulin G (IgG) in HIV-positive versus HIV-negative patients.
Methods: This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021. Specimens were tested for SARS-CoV-2 immunoglobulin G on the Abbott Architect analyser.
Results: A total of 1977/8829 (22.4%) specimens were positive for SARS-CoV-2 antibodies. Seroprevalence varied between health districts from 16.4% to 37.3%, and was 19% in HIV-positive and 35.3% in HIV-negative specimens. Seroprevalence was higher among female patients (23.6% vs 19.8%; p 0.0001) and increased with increasing age, with a statistically significant difference between the farthest age groups ( 10 years and 79 years; p 0.0001). The seroprevalence increased from 17% on 10 November 2020 to 43% on 09 February 2021 during the second wave.
Conclusion: Our results highlight that during the second COVID-19 wave in KwaZulu-Natal a large proportion of people living with HIV were still immunologically susceptible. The reduced seropositivity in people with virological failure further emphasises the importance of targeted vaccination and vaccine response monitoring in these individuals.
What the study adds: This study contributes to data on SARS-CoV-2 seroprevalence before and during the second wave in KwaZulu-Natal, South Africa, which has the highest HIV prevalence globally. Reduced seropositivity was found among people living with HIV with virological failure, highlighting the importance of targeted booster vaccination and vaccine response monitoring. |
| first_indexed | 2024-03-13T01:41:23Z |
| format | Article |
| id | doaj.art-136ecb808a7249219fc9b41ef7e7d8bf |
| institution | Directory Open Access Journal |
| issn | 2225-2002 2225-2010 |
| language | English |
| last_indexed | 2024-03-13T01:41:23Z |
| publishDate | 2023-06-01 |
| publisher | AOSIS |
| record_format | Article |
| series | African Journal of Laboratory Medicine |
| spelling | doaj.art-136ecb808a7249219fc9b41ef7e7d8bf2023-07-03T14:04:33ZengAOSISAfrican Journal of Laboratory Medicine2225-20022225-20102023-06-01121e1e610.4102/ajlm.v12i1.2065437Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South AfricaKerri-Lee A. Francois0Nokukhanya Msomi1Kerusha Govender2Lilishia Gounder3Pravi Moodley4Raveen Parboosing5Indrani Chetty6Lunga Xaba7Aabida Khan8Discipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, Durban, South Africa; and, Department of Medical Virology, Faculty of Health Sciences, University of the Witwatersrand, JohannesburgDiscipline of Virology and National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology and National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, DurbanDiscipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, DurbanBackground: KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as people living with HIV in KwaZulu-Natal, is unknown. Objective: The study aimed to determine the prevalence of SARS-CoV-2 immunoglobulin G (IgG) in HIV-positive versus HIV-negative patients. Methods: This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021. Specimens were tested for SARS-CoV-2 immunoglobulin G on the Abbott Architect analyser. Results: A total of 1977/8829 (22.4%) specimens were positive for SARS-CoV-2 antibodies. Seroprevalence varied between health districts from 16.4% to 37.3%, and was 19% in HIV-positive and 35.3% in HIV-negative specimens. Seroprevalence was higher among female patients (23.6% vs 19.8%; p 0.0001) and increased with increasing age, with a statistically significant difference between the farthest age groups ( 10 years and 79 years; p 0.0001). The seroprevalence increased from 17% on 10 November 2020 to 43% on 09 February 2021 during the second wave. Conclusion: Our results highlight that during the second COVID-19 wave in KwaZulu-Natal a large proportion of people living with HIV were still immunologically susceptible. The reduced seropositivity in people with virological failure further emphasises the importance of targeted vaccination and vaccine response monitoring in these individuals. What the study adds: This study contributes to data on SARS-CoV-2 seroprevalence before and during the second wave in KwaZulu-Natal, South Africa, which has the highest HIV prevalence globally. Reduced seropositivity was found among people living with HIV with virological failure, highlighting the importance of targeted booster vaccination and vaccine response monitoring.https://ajlmonline.org/index.php/ajlm/article/view/2065sars-cov-2 igg prevalenceseroprevalence hiv-positive and hiv-negativeanti-sars-cov-2 igg hiv-positive and negativeseroprevalence sars-cov-2 iggkwazulu-natal |
| spellingShingle | Kerri-Lee A. Francois Nokukhanya Msomi Kerusha Govender Lilishia Gounder Pravi Moodley Raveen Parboosing Indrani Chetty Lunga Xaba Aabida Khan Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa African Journal of Laboratory Medicine sars-cov-2 igg prevalence seroprevalence hiv-positive and hiv-negative anti-sars-cov-2 igg hiv-positive and negative seroprevalence sars-cov-2 igg kwazulu-natal |
| title | Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa |
| title_full | Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa |
| title_fullStr | Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa |
| title_full_unstemmed | Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa |
| title_short | Seroprevalence of SARS-CoV-2 immunoglobulin G in HIV-positive and HIV-negative individuals in KwaZulu-Natal, South Africa |
| title_sort | seroprevalence of sars cov 2 immunoglobulin g in hiv positive and hiv negative individuals in kwazulu natal south africa |
| topic | sars-cov-2 igg prevalence seroprevalence hiv-positive and hiv-negative anti-sars-cov-2 igg hiv-positive and negative seroprevalence sars-cov-2 igg kwazulu-natal |
| url | https://ajlmonline.org/index.php/ajlm/article/view/2065 |
| work_keys_str_mv | AT kerrileeafrancois seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT nokukhanyamsomi seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT kerushagovender seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT lilishiagounder seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT pravimoodley seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT raveenparboosing seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT indranichetty seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT lungaxaba seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica AT aabidakhan seroprevalenceofsarscov2immunoglobulinginhivpositiveandhivnegativeindividualsinkwazulunatalsouthafrica |